Is Morpheus8 Safe for Darker Skin? What the Documents Say

One line in the manufacturer’s own marketing describes this device as “safe for all skin types, including Fitzpatrick VI”. It is repeated across UK clinic pages without qualification, and it is the Morpheus8 claim most worth reading against the paperwork. Because the paperwork does not say that. The FDA clearance limits the device by skin type. The manufacturer’s operator manual tells practitioners to treat darker skin with caution, caps the energy they may use, and describes weeks of prescribed skin preparation. The review literature tells them to turn the energy down further still, and to leave one of the tips in the drawer. None of that means darker skin cannot be treated. It means the real procedure is more constrained than the advertised one, and every constraint is written down somewhere you can ask a clinic about.

What the clearance actually restricts

Start with the regulatory position. Morpheus8 is 510(k) cleared by the FDA, not FDA approved: a substantial equivalence pathway in which a manufacturer shows a device is similar enough to one already on the market. Clearance is not a finding that a device works for any cosmetic purpose, and no Morpheus8 clearance names wrinkles, skin tightening, acne scars, cellulite, stretch marks, body contouring or fat reduction. The cleared wording covers electrocoagulation, haemostasis, and coagulation or contraction of soft tissue.

Inside that clearance sits a restriction which almost never reaches consumer copy. Energies above 62 millijoules per pin are limited to Fitzpatrick skin types I to IV. Types V and VI, the deeper brown and black end of the six point scale, sit outside that cleared range.

The constraint is real, and awkward to use, because the machine in front of you is not calibrated in millijoules. Its energy dial runs from 5 to 60 on the standard and body tips, and nothing published converts one scale into the other. So neither you nor, in all likelihood, the person holding the handpiece can point at a setting and say it sits below the cleared threshold. The limit exists. The translation does not. It is one of several places where the numbers on the machine and the numbers in the regulatory file refuse to line up.

What the manufacturer’s manual tells practitioners to do

The operator manual is considerably blunter than the marketing around it. Skin type V and dark VI, it says, are to be treated with caution. Energy above level 20 is not to be used in types V and VI, which removes two thirds of the dial. Treatment starts at the minimum energy the machine offers, and escalation is limited to 5 levels per visit, with 3 to 4 weeks between visits.

That is a schedule, not a setting: someone with Fitzpatrick VI skin who starts at the bottom and climbs 5 levels a visit is on a deliberately slow ramp, each session testing the response before the next goes higher. It is a different rhythm from the fixed setting course most package pricing assumes.

Two general instructions matter more here than anywhere else: use the lowest output setting necessary, and perform a test spot in an inconspicuous area before a first full session, because the higher the energy applied, the greater the possibility of unintended thermal damage. On skin with more pigment in it, a test spot is not a formality. It is the only patient specific information anyone in the room will have.

The preparation regimen that never appears in the advertising

The surprise sits in the manufacturer’s own aftercare instructions. For Asian patients and Fitzpatrick types IV to V, the manual states that a physician may prescribe a bleaching regimen for 6 to 12 weeks, applied 2 to 3 times weekly once healing is complete, which it puts at around 7 days, and stopped 48 to 72 hours before the next session. The stated purpose is to minimise the risk of post-inflammatory hyperpigmentation.

Notice what that implies: a prescribed medical regimen running alongside the course, for months, on the manufacturer’s own recommendation, for a large share of the population. No agent or concentration is named in the public documents. But a clinic treating a patient in that range should be able to say whether it intends to follow the instruction at all, and if not, why not.

The sun protection instructions are unqualified too: SPF 30 or higher, protection of the treated area from over exposure to sunlight for at least one month, and no excessive tanning of any kind for the entire course. The manual attaches no skin type exemption to any of it, which is worth saying plainly, because the assumption that darker skin can skip that step is common. What that month looks like alongside the rest of the healing sits in the results timeline.

What the independent review literature adds

The peer reviewed review literature goes further than the manual in two ways. First, it advises reducing energy by 20 to 30 percent in Fitzpatrick types IV to VI, a broader band than the manual’s cautions, since it pulls type IV in as well.

Second, it advises avoiding the 0.5 mm resurfacing tip in types V to VI. That tip is the outlier of the range: it treats the surface of the skin rather than the layers beneath, and the surface is where the pigment producing cells sit. If a course you are quoted includes a resurfacing pass, the tip is a fair thing to ask about.

The published settings were already lower

Two datasets show the adjustment being made, not merely recommended. In the largest published facial cohort, 247 patients treated for neck laxity and jowling, energy ran from 5 to 62 across the group, but darker phototypes started at 15 or below, with a maximum of 40 over soft tissue and 25 over bone. The acne and acne scarring dataset reported its parameters stratified by skin type: for types I to IV, forehead at 1 mm and energy 25 in cycle mode, cheeks at 2 to 3 mm and 30 to 45 fixed, neck at 2 mm and 30 to 40 in cycle mode, with types V to VI reduced by roughly 20 percent.

One detail deserves a question rather than a footnote. That cohort’s ceiling for darker phototypes, 40 over soft tissue, sits well above the manual’s cap of 20 for types V and dark VI, and the paper does not define which Fitzpatrick types its “darker phototypes” included. Published practice and the manufacturer’s written limit are not the same thing, so if a practitioner quotes a number from the literature, ask which document they are working from.

Who produced the reassuring data

The supportive pigment data should be read with its funding structure visible. The most quoted figure is a series of 35 Fitzpatrick VI subjects in whom no pigment alteration or scarring was reported. That is genuinely reassuring, with two caveats: the series was not Morpheus8 specific, and it reaches most readers through a review published in a journal supplement sponsored by InMode. The stratified acne parameters above come from a paper whose authors are InMode consultants, in a supplement sponsored by InMode, although those authors state they purchased their own devices. That structure covers a large share of this device’s literature. It does not make the findings wrong. It does mean citing “multiple published studies” without saying who paid for the supplement is not an honest summary.

The reassurance and the caution come from the same company. Only one of them makes it into the advertising.

What is missing is more telling. No sham controlled randomised trial of Morpheus8 has been published at all, and the one independent systematic review that excluded industry funded studies rates the radiofrequency microneedling evidence base at Level of Evidence 5, the lowest rung. That review names post-inflammatory hyperpigmentation among the key risks of the modality, and states plainly that the highest conferred risk of complications was user error. The manufacturer’s own adverse event list includes pigmentary change in both directions, along with burns and scarring. And on 15 October 2025 the FDA issued a safety communication on radiofrequency microneedling as a class, reporting burns, scarring, fat loss, disfigurement, nerve damage and the need for surgical repair, and stating that this is a medical procedure, not a cosmetic treatment.

Nowhere in any of it is there a rate. No published figure says how often pigment change follows this treatment in any skin type, let alone broken down by Fitzpatrick score. If a clinic offers you a percentage, ask where it came from.

What this means in the consultation room

The verdict is neither the marketing’s nor the alarmist one. Darker skin is treated with this device, and the manufacturer has written down how to do it more carefully. Almost none of that care appears in the copy that persuades people to book, which leaves the reader to check their practitioner knows it.

Five questions do most of the work. Which Fitzpatrick type do you think I am, and how did you decide? What energy will you start me at, and what is your ceiling for my skin? Will you do a test spot before the first full session? Do you intend to prescribe anything before or between sessions, and if not, why not? And if my skin darkens after session one, what happens to the plan? A practitioner working from the documents will answer all five without hesitating, and there are more questions worth taking with you into the room.

One thing first. If you have an existing pigmentary condition, or an area of skin that has changed and has never been looked at, that needs a diagnosis from your GP or a dermatologist before any energy device is pointed at it. Once that is settled, book a consultation with us and we will go through skin type, starting energy, escalation, preparation and test spotting in plain numbers, alongside an honest view of whether this is the right tool for what is bothering you.